You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Veracyte said on Tuesday that it has partnered with Bayer to launch the Precision Oncology Patient Identification Program in thyroid cancer, which will focus on identifying patients who may benefit from biomarker-driven therapies.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.
Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.
Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.